Reaction
Keratoacanthoma reporting signals
As of the last recalculation, Keratoacanthoma appears in 671 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is VEMURAFENIB (PRR 321.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Vemurafenib | 105 | 321.1 | 323.9 |
| Sorafenib | 25 | 38.7 | 38.8 |
| Lisinopril And Hydrochlorothiazide Tablets | 8 | 31.9 | 32.0 |
| Dabrafenib | 20 | 30.3 | 30.3 |
| Encorafenib | 9 | 28.6 | 28.6 |
| Lisinopril And Hydrochlorothiazide | 9 | 27.7 | 27.7 |
| Felodipine Extended-Release Tablets | 8 | 22.0 | 22.1 |
| Felodipine | 8 | 22.0 | 22.1 |
| Imatinib | 9 | 16.0 | 16.0 |
| Nivolumab | 46 | 15.8 | 15.8 |
| Tofacitinib Citrate | 6 | 14.3 | 14.3 |
| Trametinib | 10 | 13.0 | 13.0 |
| Guselkumab | 7 | 6.1 | 6.1 |